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The hepatocyte contains a battery of membrane trans-
porters in the sinusoidal and canalicular membrane that
guarantee the regulated import and export of nutrients,
messengers and toxic compounds. In the canalicular
membrane, a number of important ABC (ATP binding
cassette) transporters are located. Three of these pri-
mary active transporters, BSEP (bile salt export pump,
ABC B11), MDR3 (multidrug resistance protein 3, ABC
B4) and ABC G5/G8 catalyze the secretion of bile acids
(BSEP), phosphatidylcholine (MDR3) and cholesterol
(ABC G5/G8). These three molecules form mixed
micelles in bile and thereby reduce the harmful action
of unbound bile salts on membranes.
BSEP, which was initially named s-Pgp (sister of P-gp)
and MDR3 share a high sequence identity with MDR1
(P-glycoprotein, ABC B1), which is the hallmark of the
family of multidrug resistance ABC transporter present
in every eukaryotic cell. For BSEP the identity is approxi-
mately 70% and for MDR3 even 85%, respectively. Never-
theless, MDR3 is specific for phosphatidylcholine lipids
and BSEP is specific for bile acids, while MDR1 is capable
of translocating a myriad of structurally unrelated com-
pound across biological membranes. This of course raises
the question, which residues impose specificity in the
case of BSEP and MDR3 and which residues impose pro-
miscuity in the case of MDR1.
Homology models of BSEP and MDR3 were generated
based on the crystal structures of Sav1866 and mouse
P-gp to obtain initial information about the putative
three-dimensional location of certain amino acid resi-
dues of BSEP and MDR3. However, one has to stress
that these “structures” represent only models that have
to be used with proper caution. The homology model of
MDR3 was helpful in providing a structural explanation
for the non-functionality of the MDR3 mutant H1231Y.
The mutant protein was properly located to the plasma
membrane, but displayed a severe substrate transport
phenotype. Histidine 1231 corresponds to the histidine
of the H-loop, a residue that is critical for ATP hydroly-
sis in many other ABC transporter systems. Thus,
exchange of His against Tyr in position 1231 of MDR3
will impair ATP hydrolysis in one of the two ATP bind-
ing site drastically reducing transport activity of MDR3
H1231Y [1].
To study the transport cycle and the importance of
mutations within these transporters on their function,
overexpression systems are required. We decided to use
the methylotrophic yeast Pichia pastoris for the overex-
pression of two of the three transporters, BSEP and
MDR3, respectively. Initially we encountered severe pro-
blems in cloning the transporters genes in E. coli employ-
ing standard approaches. Only after establishing a
cloning strategy that is entirely based on Saccharomyces
cerevisiae, both genes could be successfully cloned [2].
This allowed us to combine the speed and ease of cloning
of this yeast system for the wild type genes and mutations
that were identified in patients.
Having this tool in hand, we overexpressed BSEP in
yeast to study its transport function in plasma membrane
vesicles. This allowed us to establish structure-function
relations for a new clinically relevant mutation (G374S)
that resulted in a phenotype between PFIC-2 and BRIC-2.
Although membrane targeting was normal, e.g. targeting
to the canalicular membrane was evident, transport activ-
ity of the G374S was strongly impaired [3]. The Sav1866-
based homology model of BSEP suggested that Gly 374 is
lining the translocation pore of BSEP. Thus, an exchange
to serine would impose steric restriction within the pore,
thereby influencing the substrate spectrum as evident
from the bile acid transport assays.Correspondence: lutz.schmitt@hhu.de
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Based on the expression levels of BSEP and MDR3,
purification protocols for both membrane proteins were
successfully established [4]. Thus, next to the transport
assay that is based only highly enriched yeast plasma
membranes, purified protein is now also available in the
detergent-solubilized state. While the transport assay
can be used for BSEP to analyze a possible influence of
a mutation on the transporter activity of the protein,
purified MDR3 can be used to determine the influence
of a mutation on ATPase activity and / or stimulation
or inhibition of this activity.
In summary, the established yeast overexpression system
combines the ease and speed of yeast cloning approaches
with the possibility to overexpress and purify both proteins
in a quantity and homogeneity sufficient for biochemical
and biophysical investigations of the function of these two
ABC transporters. Furthermore, the speed with which
mutants can be obtained will allow an in depth characteri-
zation of clinically relevant mutations of both transporters
with respect to function and spectrum of transported
substrates.
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